Showing 531-540 of 618 results for "".
- Vision Integrated Partners Completes Refinancinghttps://modernod.com/news/vision-integrated-partners-completes-refinancing/2482123/Vision Integrated Partners (VIP) has successfully completed a recapitalization that consist of $25 million revolving credit facility, a $155 million term loan, and a $12.5 million delayed draw term loan. Proceeds from the credit facilities will be used to refinance existing indebte
- Adverum Biotechnologies Raises $127.5 Million to Advance Gene Therapy Pipelinehttps://modernod.com/news/adverum-biotechnologies-raises-1275-million-to-advance-gene-therapy-pipeline/2482099/Adverum Biotechnologies has agreed to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional and accredited healthcare investors in a private placement. Adverum anticipates the gross proceeds from the private placement to be
- EyeBio Announces Expansion of Series A to $130 Million to Advance Development of Restoret for Retinal Diseaseshttps://modernod.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/Eyebiotech announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the company’s clinical development program and further build out its retina pipeline.
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha
- Outlook Therapeutics Closes $55 Million Financing; Extends Cash Runway Through Anticipated FDA Approval of ONS-5010https://modernod.com/news/outlook-therapeutics-closes-55-million-financing-extends-cash-runway-through-anticipated-fda-approval-of-ons-5010/2481313/Outlook Therapeutics announced it closed on approximately $25 million registered direct equity offering, and about $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2. The $50 million net proc
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fundhttps://modernod.com/news/nacuity-pharmaceuticals-announces-165-million-series-b-financing-led-by-foundation-fighting-blindness-rd-fund/2480913/Nacuity Pharmaceuticals announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Proceeds from the financing will be used to support the advanc
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Aurion Biotech Raises $120 Million to Advance its Cell Therapy Programhttps://modernod.com/news/aurion-biotech-raises-120-million-to-advance-its-cell-therapy-program/2480760/Aurion Biotech announced it has secured a $120 million financing with biotech and ophthalmology investors. The company intends to use the proceeds of the financing to advance its cell therapy program for corneal edema secondary to endothelial dysfunction, which affects approximately 16